Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02453282 · ClinicalTrials.gov registry record · Phase 3
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
A Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 1,118
- Enrollment target
- 20
- Study locations
NCT02453282 is a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,118 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT02453282, a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,118 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC
Conditions Studied
Interventions
- BIOLOGICAL MEDI4736 (Durvalumab)
- BIOLOGICAL MEDI4736 (Durvalumab)+Tremelimumab
- DRUG Paclitaxel + Carboplatin
- DRUG Gemcitabine + Cisplatin
- DRUG Gemcitabine + Carboplatin
Study Locations (20)
California
- Research Site - Bakersfield
- Research Site - Fullerton
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Redondo Beach
- Research Site - Sacramento
- Research Site - San Luis Obispo
- Research Site - Santa Maria
- Research Site - West Hollywood
Arizona
- Research Site - Scottsdale
- Research Site - Tucson
- Research Site - Yuma
Florida
- Research Site - Jacksonville
- Research Site - Pembroke Pines
- Research Site - Tampa
Connecticut
- Research Site - New Haven
Georgia
- Research Site - Athens
Hawaii
- Research Site - Honolulu
Maryland
- Research Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,118 participants |
| Start Date | 2015-07-21 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02453282
The ClinicalTrials.gov registry entry for NCT02453282 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma NSCLC appearing as the primary indexed condition, and to 5 interventions - of which MEDI4736 (Durvalumab) is the first listed.
NCT02453282 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT02453282 about?
NCT02453282 is a clinical study titled "Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)". This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (E...
What is the current status of trial NCT02453282?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,118 participants. The study started on 2015-07-21. Estimated completion is 2026-12-31.
What conditions does trial NCT02453282 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma NSCLC.
What interventions are being tested in trial NCT02453282?
The interventions under investigation include: MEDI4736 (Durvalumab) (BIOLOGICAL), MEDI4736 (Durvalumab)+Tremelimumab (BIOLOGICAL), Paclitaxel + Carboplatin (DRUG), Gemcitabine + Cisplatin (DRUG), Gemcitabine + Carboplatin (DRUG).
Who is sponsoring clinical trial NCT02453282?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02453282 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.